SCHEMBL220538

SCHEMBL220538

Nc1cc(C(=O)O)ccn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 3/20 1.00
GABRD O14764 3/20 1.00
GABRA1 P14867 3/20 1.00
GABRB1 P18505 3/20 1.00
GABRG2 P18507 3/20 1.00
GABRB3 P28472 3/20 1.00
GABRA5 P31644 3/20 1.00
GABRA3 P34903 3/20 1.00
GABRA2 P47869 3/20 1.00
GABRB2 P47870 3/20 1.00
GABRA4 P48169 3/20 1.00
GABRE P78334 3/20 1.00
GABRA6 Q16445 3/20 1.00
GABRG1 Q8N1C3 3/20 1.00
GABRG3 Q99928 3/20 1.00
GABRQ Q9UN88 3/20 1.00
KDM4C Q9H3R0 7/20 0.61
KDM5C P41229 6/20 0.61
KDM2A Q9Y2K7 5/20 0.61
KDM3A Q9Y4C1 5/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30705741 1.00 GABRP (1.00) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL22797869 0.98 GABRP (0.96) GABRPGABRDGABRA1GABRB1GABRG2
Nitrous Acid SCHEMBL28394532 0.92 GABRP (0.85) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL446809 0.83 GABRP (0.70) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL31661275 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1159738 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL19586492 0.81 GABRP (0.68) GABRPGABRDGABRA1GABRB1GABRG2
Hydrochloric Acid SCHEMBL6227701 0.79 GABRP (0.66) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1417739 0.78 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL26093618 0.78 GABRP (0.63) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 709 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122037226-A Bimetallic-organic framework material for trapping trifluoromethane, preparation method thereof and adsorbent based on bimetallic-organic framework material 西安交通大学 2026-05-15 CN claimed
CN-119753728-A Preparation method of ordered defective indium cluster frame porous material for electrocatalytic conversion of carbon dioxide to urea 东北师范大学 2025-04-04 CN claimed
CN-119659103-A Non-woven fabric welding coating and preparation method thereof 华洋(苏州)新材料科技有限公司 2025-03-21 CN claimed
US-12151046-B2 Composite antibacterial hydrogel dressing, preparation method and application thereof GUANGDONG OCEAN UNIVERSITY (CN) 2024-11-26 US claimed
US-20240277894-A1 COMPOSITE ANTIBACTERIAL HYDROGEL DRESSING, PREPARATION METHOD AND APPLICATION THEREOF GUANGDONG OCEAN UNIVERSITY (CN) 2024-08-22 US claimed
WO-2024139662-A1 COMPOSITE ANTIBACTERIAL HYDROGEL DRESSING, PREPARATION METHOD THEREFOR, AND USE THEREOF 广东海洋大学 2024-07-04 WO claimed
US-11992563-B2 Composite material for rapid blood clotting and preparation method thereof GUANGDONG OCEAN UNIVERSITY (CN) 2024-05-28 US claimed
CN-118005944-A Antibacterial metal organic framework composite material and preparation method and application thereof 中国科学院赣江创新研究院 2024-05-10 CN claimed
CN-117696012-A Metal organic framework material and preparation method and application thereof 浙江大学 2024-03-15 CN claimed
CN-117659427-A Cd-3-aminopyridine-4-formic acid-MOFs material and preparation method and application thereof 河南师范大学 2024-03-08 CN claimed
EP-3317252-A1 A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID Boehringer Ingelheim International GmbH (DE) 2018-05-09 EP claimed
US-9783905-B2 Reaction products of amino acids and epoxies Rohm and Haas Electronic Mateirals LLC (US) 2017-10-10 US claimed
US-20170218533-A1 REACTION PRODUCTS OF AMINO ACIDS AND EPOXIES U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2017-08-03 US claimed
CN-105237472-B Substituted pyridine complex and preparation method therefor as well as application of substituted pyridine complex as nonlinear optical material, ferroelectric material and fluorescent material 淮南师范学院 2017-02-15 CN claimed
WO-2017001670-A1 A GENERAL PROCESS FOR THE PREPARATION OF 6-SUBSTITUTED OR 5,6-DISUBSTITUTED DERIVATIVES OF 2-AMINO-ISONICOTINIC ACID BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-01-05 WO claimed
CN-105237472-A Substituted pyridine complex and preparation method therefor as well as application of substituted pyridine complex as nonlinear optical material, ferroelectric material and fluorescent material UNIV HUAINAN NORMAL 2016-01-13 CN claimed
CN-104130256-A Preparation method for pyridine[3, 4-d]pyrimidine-4(3H)-one derivative BIDE PHARMATECH LTD 2014-11-05 CN claimed
WO-2007117482-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 WO claimed
US-20020010344-A1 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade PHARMACIA CORPORATION 2002-01-24 US claimed
EP-0409119-B1 N,N'-Bis(alkoxy-alkyl)-pyridine-2,4-dicarboxylic acid amides, process for their preparation as well as their use HOECHST AG (DE) 1994-04-13 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010344-A1 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade TFPI, SERPINC1, F2 GABRP 3231/4885GABRD 2293/4885GABRA1 2858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.